Introduction
Behçet's disease (BD) is a multisystem vasculitis with unknown etiology characterized by the heterogeneous nature of organ involvement and a fluctuating disease course (1) (2) (3) . In the clinical practice, it is not possible to define a uniform or standard therapy for BD, since the symptoms widely variable. The management should be tailored to each patient by taking into account the existing symptoms, clinical manifestations and prognostic factors (3) . Vascular relapse risk is decreased when BD patients are treated with immunosuppressives with or without anti-coagulation rather than anti-coagulation alone (1) . There are various effective treatment alternatives, while, the first and essential step for a successful treatment is patients' adherence to therapy. On the other hand, it is estimated that in developed countries, 40% of patients who suffer from chronic diseases do not adhere to treatment recommendations (4) . Moreover, negative attitudes to medicines appear to be prevalent within the community, with many patients being suspicious of medicine, which further disturbs the adherence to treatments. Efforts to improve treatment outcomes require a better understanding of the particular barriers to and facilitators of adherence to therapy, and of patient experiences of taking treatment (5) . Treatment adherence is influenced by many factors, among them: i) route of administration, ii) psychosocial factors, iii) fear of side effects, iv) lack of an immediate feeling of benefit, and v) patient attitudes to health and disease and beliefs about medicines (6) (7) (8) (9) . The causes of nonadherence can be summarized as unintentional and intentional. Intentional nonadherence occurs when the patient decides not to take medication as advised, and appears to be related to patients' beliefs, and their motivation to take the prescribed medication, whereas unintentional nonadherence
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Behçet's disease patients from 18 countries demonstrate that nonadherence is often linked to doubts about their personal need for the treatment (Necessity beliefs) and to concerns about potential adverse consequences of taking it. In these studies Necessity beliefs and Concerns were assessed using the Beliefs about Medicines Questionnaire (BMQ) © . The BMQ is composed of two sections: the General section (BMQ-General), which assesses more general beliefs about medicine and includes the General Harm and the General Overuse scales; and the Specific section (BMQSpecific), which explores beliefs about particular medication and comprises the Specific Necessity and Specific Concerns scales (10, 16) . The BMQ has been adapted and used in many countries (6, 9, 12, 17) , but it has not yet been adapted to the Turkish language. In addition, as far as we know, there is no study assessing the belief about the medicine of patients with BD. In the present study, we aimed to investigate the validity and reliability of a Turkish translation of the BMQ in patients with BD.
Methods

Study design, sample and setting
The study was planned and applied as a methodological study. This study was conducted in a single rheumatology center. The study was approved by the Ethical Review Board of the hospital and written informed consent was obtained from each participant. Patients with BD who were being followed-up at the tertiary rheumatology outpatient clinic were invited to participate to the study. The inclusion criteria for the study as follows: i) fulfilling the International Study Group Criteria for BD (18) ; ii) being at age 18 years or older; iii) ability to read and write Turkish; iv) willingness to participate; and v) physically and cognitively able to communicate. The exclusion criteria consist of: i) having a major psychiatric disease diagnosis; ii) having cognitive impairment; iii) concurrent terminal illness or being clinically unstable. Ultimately, a total of 140 patients with BD were enrolled in the study. Of these, 15 patients did not complete the all questionnaires, who were omitted from the analysis. Consequently, data analyses were subjected to remaining 125 patients. A mean score for each scale are computed by dividing total scores for that scale by the number of items in the scale, resulting in a mean score range of 1-5 for each scale. Higher scores indicate stronger beliefs in the concepts represented by the scale. A necessityconcerns differential is calculated as the difference between the necessity and the concerns scales, with a possible range of -4 to +4. This differential can be thought of as an indicator of how the individual judges their personal need for the treatment (necessity beliefs) relative to their concerns about taking it (10, 16).
Demographic and disease-related variables
Morisky Medication Adherence Scale (MMAS)
Medication adherence was assessed using the Morisky Medication Adherence Scale, which is a validated and reliable measure, developed by Morisky, Green, and Levine (1986). In this scale, patients were asked to respond "yes" or "no" to the following questions: Do you ever forget to take your medicine? Are you careless at times about taking your medicine? Do you sometimes stop taking your medicine when you are feeling well? When you feel worse due to the medicine, do you stop taking it? Adherence was assessed on a scale of 0 to 4, in which higher scores correspond to lower medication adherence and vice versa. Participants were then stratified into three groups according to their scores: 0 = high medication adherence; 1, 2 = medium medication adherence; 3, 4 = low medication adherence (21, 22) .
Procedure
Written authorization to translate the original English version of the BMQ into Turkish was obtained from the Originator (Prof. Rob Horne UCL School of Pharmacy, University College London). The English version was independently translated into Turkish by two bilingual (Turkish and English) experts. One of them was a registered nurse and the other was a rheumatologist. A third bilingual expert reviewed the two Turkish-translated versions and created another version. This version was back translated to English by two bilingual experts who had not read the original version. Thereafter, all three versions (original, translated, and back-translated) were assessed by a panel of three bilingual experts in the field (23, 24) . Following the translation/back-translation procedure, the final version was checked using a pretest technique to verify that they were able to understand the instructions, the questions, and the different answering options (24, 25) and to ensure that the language used fits the target population of the scale. Two weeks later, the Turkish version of the BMQ was administered again to 41 patients. These results were used to evaluate test-retest reliability.
Data analysis
All statistical analyses were conducted using the SPSS for Windows version 21.0 statistical software (IBM Inc, USA). Descriptive statistics (means, standard deviations [SDs], frequency distributions, percentages) were computed. Internal consistency of BMQ-Turkish Translation (BMQ-T) was evaluated by Cronbach's alpha coefficient from baseline results of the patients. The BMQ-T questionnaire was applied two times at a two-week interval by the same researcher. Intraclass correlation coefficient (ICC) was calculated to assess test-retest reliability, and the paired samples t test was performed to represent there is no differences between first and second BMQ-T points. The measure validity of the BMQ was assessed by computing the correlation coefficient between the BMQ-T scores and the MMAS. Patients were grouped in three categories according to MMAS scores. Mean BMQ scores of these groups were compared using ANOVA, with Tukey HSD as the post hoc test. Construct validity was evaluated by exploratory factor analysis. Principle component analysis (PCA) was conducted with varimax rotation. The Kaiser-Meyer-Olkin test was performed to evaluate sample adequacy. The number of components was determined according to eigenvalue. In this study, p values less than .05 were considered to be statistically significant.
Results
Participant characteristics
A total of 125 patients had completed the study protocol. The mean age of these patients was 31.42±8.11 years. Mean disease duration was 9.34±5.76 years. The study population was male predominant (91.2%) and about half of the patients were single (53.6%). Twenty-nine (23.2%) of the patients were primary school graduate, 41 (32.8%) were high school graduate, and 55 (44.0%) were university and higher graduate. All of the patients had current or a history of oral aphthae. Other skin lesions, such as papulopustular lesions, genital ulcers, and erythema nodosum were present in 96.0%, 84.8%, and 52.0% of the patients, respectively. The most frequent organ involvement was ocular disease with a frequency of 41.6%. Other involvements such as joint, vascular, central nervous system, and gastrointestinal diseases were seen in 29.6%, 17.6%, 5.6%, and 0.8% of patients, respectively. The pathergy test was positive in 46.4% of the patients. The HLA-B51 test was positive in 30 of 43 patients who were tested. The clinical features of the study group are presented in Table I . Among the current treatment agents, colchicine was the most commonly used one (76.8%). Sixty-seven patients were using at least one immune suppressive drug (azathioprine, cyclosporine A and cyclophosphamide). Other medications such as corticosteroids and anticoagulant agents were being used in 20 and 9 patients, respectively. Other medicines including infliximab, sulfasalazine, methotrexate, and nonsteroidal anti-inflammatory drugs (NSAIDs) were being used by a minority of the patients (each, <5%). (Table II) .
Validity
The Morisky scale classifies patient adherence as high, medium, and low. In our comparative analysis, a statistically significant difference was found between these groups with respect to the total BMQ-T scores (except for BMQ-T-General Harm). We performed a post hoc analysis to identify the cause of this difference; we found that the BMQ-T-Specific Necessity mean score of patients with high Morisky drug adherence was higher from those in the medium and low drug adherence groups (p=.022), BMQ-T-Specific Concerns mean score of patients with high Morisky drug adherence was lower from those in the medium and low drug adherence groups (p=.006) and BMQ-TGeneral Overuse mean score of patients with medium Morisky drug adherence was lower from those in the low drug adherence groups (p=.024) (Table III) . There was no correlation between BMQ-T-General Harm score and both the total MMAS and classified MMAS scores. Construct validity was evaluated by factor analysis. The original scale consisted of four components. As a result of our analysis, that the items separated into four components in Principle Component Analysis. The total explained variance was 54.73%, and the lowest item load was .46. The Kaiser-MeyerOlkin measure of sample adequacy was found to be .71 (Table IV) . At the result of the PCA, item 5 was classified more closely with General Overuse questions, rather than its components. But the factor load with Specific Concerns questions was calculated as .318. The factor structure we have achieved was considered to be highly consistent with the original structure of the scale, and it had an appropriate and close scoring and classification to the original. We calculated a Necessity Concerns Differential (NCD) by subtracting mean Concerns Scale scores from Necessity scale scores (scale scores range from -4 to +4). The mean NecessityConcerns differential was found to be 0.47±0.91 (range -1.8 to 3).
Discussion
This was the first study to assess the reliability and validity of the Turkish translation of the BMQ. The prevalence rate of BD was between 20-421 among 100,000 in adolescent/adult population in Turkey (26) (27) (28) . BD, for many patients, is a disease that impairs the quality of life by frequently relapsing mucocutaneous manifestations. However, there are also many who carry an increased risk of significant morbidity or even mortality as a consequence of vital organ involvement. Many factors, including patient's sex, age of disease onset, the disease duration and patient attitudes and beliefs about medication need to be considered when planning treatment for a patient with BD. In this context, we decided to conduct the study in these patients. This study results supported the validity and reliability of the BMQ-T. The BMQ-T showed adequate reliability for clinical application. Internal consistency of the total BMQ-T (Specific and General) was supported by Cronbach's alpha coefficients (.774 and .730 respectively). In the correlation analysis performed for the test-retest reliability, an adequate statistically significant and positive correlation was observed between the first test and the retest scores (Table II) . The validity of the BMQ- (16) . These previous studies validating the BMQ-T indicate this scale has adequate reliability, and similar results were found in our study. In our study, the construct validity of the scale was evaluated by factor analysis. The Kaiser-Meyer-Olkin measure of sample adequacy was found to be .71 and considered adequate. The total explained variance was 54.73%, and the lowest item load was .46. The factor structure we have achieved was considered to be highly consistent with the original structure of the scale, and it had an appropriate and close scoring and classification to the original (Table  IV) . Finally, the construct validity of our translated questionnaire was evaluated as satisfactory. The MMAS is commonly used in medication adherence studies (13) . Morisky et al. (21) developed a brief, easily understood, and valid scale to be administered to patients in the clinical setting. In the present study, the medication adherence was evaluated with MMAS. According to the MMAS scores, medium and high levels of medication adherence were observed in the majority of the patients. While reported average medication adherence scores range between 43-78% in clinical trials, it is estimated that in developed countries (31), 40% of patients who suffer from chronic diseases do not adhere to treatment recommendations (4) . In the present study, medication adherence in BD patients seems to be better as compared to the historical data in other patient populations, while to our knowledge no data existed in BD patients. While we categorized our data into three groups according to MMAS scores, there was a statistically significant difference among these groups for BMQ-T scores except for BMQ-TGeneral Harm (Table III) . It has been reported that General Harm and General Overuse beliefs were associated with Specific Concerns about medication prescribed for them by their doctors (7, 16 In our study, similar to the original version and previous studies, both general and specific parts of the scale was found to be validated. Patient's with stronger beliefs in the necessity of their medication (high scores on the BMQ-Necessity scale) were significantly more adherent. Those with stronger concerns (high scores on the BMQ-Concerns scale) were significantly less adherent (10) .
In our study, we also found similar results. We have found that, the patients with higher drug adherence had also higher Specific Necessity scores, those with lower drug adherence, had higher Specific Concerns scores. The Turkish translation of the BMQ exhibited good to excellent internal consistency and its structure and content provided a perfect fit to those of the original questionnaire. Our findings underscore the usefulness of the BMQ-T for assessing beliefs that patients with BD hold about the medicines they use. Therefore, further studies are needed to investigate the reliability and validity of this scale in different clinical settings and different populations.
Conclusion
The Turkish version of the BMQ is a simple, and inexpensive to administer, and a convenient measurement of patients' attitudes and beliefs about their medication in patients with BD. In addition, it was demonstrated to have acceptable reliability and validity.
Limitation
This study depends on a patient-reported questionnaire; therefore, this is a potential limitation of the present study. Natural drawbacks of this type of study, such as recall bias and false declarations of patients, might cause potential risk of bias.
